Cell Signaling Technology

Product Pathways - Tyrosine Kinase / Adaptors

Sunitinib #12328

Molecular Formula:
C22H27FN4O2•C4H6O5
Molecular Weight:
532.56 g/mol
Purity:
>99%

Directions for Use

Sunitinib is supplied as a lyophilized powder. For a 5 mM stock, reconstitute the 10 mg in 3.76 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 0.1-10 µM either as a pretreatment for 0.5-2 hr prior to treating with a stimulator or is used alone with varying treatment times lasting up to 24 hr. Sunitinib is soluble in DMSO at 40 mg/ml; poorly soluble in ethanol and water with maximum solubility in water ~10-50 µM.

Western Blotting

Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, serum-starved overnight and untreated or treated with hPDGF-BB #8912 (100 ng/ml, 5 min) either with or without Sunitinib pre-treatment (2 hr) at the indicated concentrations, using Phospho-PDGF Receptor β (Tyr1009) (42F9) Rabbit mAb #3124 (upper) or PDGF Receptor β (28E1) Rabbit mAb #3169 (lower).

Structure

Structure

Chemical structure of sunitinib.

Background

Sunitinib, also known as SU11248, is a multi-tyrosine kinase inhibitor widely known to target PDGFR, VEGFR, KIT, and FLT3, and therefore has both antitumor and antiangiogenic activities. Cellular phosphorylation assays show that sunitinib effectively inhibits ligand-dependent phosphorylation of these receptor tyrosine kinases in nanomolar concentrations and can also inhibit ligand-dependent cellular proliferation (1-3). Sunitinib displays greater than 10-fold selectively for PDGFRB and VEGFR over numerous other kinases, including EGFR, Cdk2, Met, IGF -1R, Abl, and src (2). Inhibition of CSF-1 (4) and RET (5) by sunitinib has also been observed.

  1. Abrams, T.J. et al. (2003) Mol Cancer Ther 2, 471-8.
  2. Mendel, D.B. et al. (2003) Clin Cancer Res 9, 327-37.
  3. O'Farrell, A.M. et al. (2003) Blood 101, 3597-605.
  4. Guo, J. et al. (2006) Mol Cancer Ther 5, 1007-13.
  5. Broutin, S. et al. (2011) Clin Cancer Res 17, 2044-54.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

For Research Use Only. Not For Use In Diagnostic Procedures.

Products